Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Liabilities and Shareholders Equity (2021 - 2025)

Prime Medicine's Liabilities and Shareholders Equity history spans 5 years, with the latest figure at $342.7 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 15.2% year-over-year to $342.7 million; the TTM value through Dec 2025 reached $1.3 billion, up 11.12%, while the annual FY2025 figure was $342.7 million, 15.2% up from the prior year.
  • Liabilities and Shareholders Equity reached $342.7 million in Q4 2025 per PRME's latest filing, down from $385.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $385.0 million in Q3 2025 to a low of $193.9 million in Q4 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $296.3 million, with a median of $301.9 million recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: tumbled 46.2% in 2023, then surged 53.47% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $301.9 million in 2021, then increased by 19.37% to $360.3 million in 2022, then tumbled by 46.2% to $193.9 million in 2023, then skyrocketed by 53.47% to $297.5 million in 2024, then rose by 15.2% to $342.7 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Liabilities and Shareholders Equity are $342.7 million (Q4 2025), $385.0 million (Q3 2025), and $279.0 million (Q2 2025).